Skip to main content
TipRanks
Go Ultimate75% OFF

Corcept Therapeutics (CORT) Q3 2026 Earnings Report

1,349 Followers

CORT Q3 2026 EPS Results

Actual EPS
$1.01
Consensus EPS
$0.84
Beat/Miss
Beat by +$0.17
One Year Ago EPS
$0.16

CORT Q3 2026 Revenue Results

Actual Revenue
$340.47M
Expected Revenue
$339.13M
Beat/Miss
Beat by +$1.35M
YoY Revenue Growth
+63.97%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/03/2026
Time
After Close
Conference Call
Tuesday, November 3, 2026
CORT Upcoming Earnings

Corcept Therapeutics's next earnings date is estimated for March 2, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

CORT Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 03, 2026|% Change Since:-17.26%|
Earnings Call Sentiment|Positive

The call was strongly positive, with substantial revenue and net-income growth, record endocrinology performance, rapid Lifyorli adoption, positive clinical results and multiple advancing pipeline programs. The company also reiterated its 2026 revenue guidance and highlighted significant future opportunities in Cushing's syndrome, oncology, MASH and ALS. The main negatives were the prior complete response letter for relacorilant, the continuing underdiagnosis of hypercortisolism, the unmet need in platinum-resistant ovarian cancer and limited available information on a potential competing therapy.

Company Guidance

Corcept reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, with the midpoint of the range as its best thinking, and said it expects growth to continue; it expects its current Cushing's syndrome business to generate at least $2 billion in annual revenue by the end of this decade, with the availability of relacorilant driving faster growth to between $3 billion and $5 billion in 2030, while Lifyorli is expected to generate more than $1 billion. The company expects results from its BELLA, TRIDENT and SYNERGY studies by the end of next year, plans to begin a Phase III study in ALS next year, and will soon start a Phase II MASH trial evaluating 100 milligrams of miricorilant daily.

  • Strong Third-Quarter Financial PerformanceThird-quarter 2026 revenue was $340.5 million, increasing 33% from the second quarter and 64% compared with the prior-year period. Net income was $126.8 million, compared with $43 million in Q2 and $19.7 million in the prior-year period.
  • Revenue Guidance ReiteratedThe company expects growth to continue and reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion. Management said the guidance reflected strength in both the endocrinology and oncology businesses and noted that the range had already been increased several times during the year.
  • Improved Cash Position and Share RepurchasesCash and investments totaled $662 million as of September 30, an increase of $118 million during the quarter. The company acquired $44 million of common stock in the third quarter pursuant to its stock repurchase program, stock option exercises and restricted stock vesting.
  • Record Endocrinology Revenue and Growing Physician AdoptionThe endocrinology division delivered another quarter of record revenue. Management said more physicians are prescribing Corcept's medicines and more patients are benefiting from them than ever before.
  • Expanded Recognition of HypercortisolismThe American Diabetes Association cited the CATALYST findings in its 2026 consensus report on type 2 diabetes and recommended screening for hypercortisolism in patients whose blood sugar remains high despite treatment with multiple glucose-lowering medications. The report also stated that mifepristone substantially reduced hemoglobin A1c in these patients. The American Association of Clinical Endocrinology had previously referenced CATALYST findings in its diabetes-management guidance issued in March.
  • Large Cushing's Syndrome Revenue OpportunityManagement expects the current Cushing's syndrome business to generate at least $2 billion in annual revenue by the end of the decade. With the availability of relacorilant, the company expects growth to reach between $3 billion and $5 billion in 2030.
  • Rapid Lifyorli Revenue GrowthLifyorli revenue reached $91.4 million in the third quarter, representing a 92% increase. Management attributed the growth to strong demand, significant unmet need in platinum-resistant ovarian cancer and increasing physician adoption.
  • Broad Lifyorli Patient and Prescriber AdoptionSince its April 1 launch, more than 1,700 physicians have prescribed Lifyorli to more than 2,300 patients. Use has expanded across gynecologists, medical and hematologic oncologists, academic and non-teaching hospitals, and community oncology clinics. Repeat prescribing is also increasing.
  • Increasing Use Earlier in TreatmentThe company reported an increasing number and proportion of patients receiving Lifyorli earlier in the treatment sequence. Management said the trend was supported by data showing that Lifyorli is particularly well suited to patients at the earliest end of its approved second- to fourth-line treatment range.
  • Positive BELLA Arm A ResultsIn BELLA Arm A, adding relacorilant to nab-paclitaxel and bevacizumab produced substantial benefits in progression-free survival, objective response rate and overall survival. The strongest responses were observed in patients earliest in their platinum-resistant treatment course. Among patients who had not previously received bevacizumab, median progression-free survival was 8.1 months, objective response rate was 66% and six-month overall survival was 91%. In the overall Arm A population, median progression-free survival was 7.2 months, objective response rate was 59% and six-month overall survival was 88%.
  • Lifyorli Launch Exceeding ExpectationsManagement said Lifyorli's launch has exceeded expectations, that the product is on its way to becoming the market-share leader in platinum-resistant ovarian cancer and that it is expected to generate more than $1 billion.
  • Relacorilant NDA Resubmitted and Under FDA ReviewFollowing a complete response letter received at the end of the prior year, the company conducted the FDA-requested global statistical test covering glucose, weight and hypertension endpoints. Management described the results as very positive, resubmitted the NDA in June, and said the FDA accepted it for review. The PDUFA date is December 17.
  • Relacorilant Demonstrated Cushing's Syndrome BenefitsManagement said data from the Phase III GRACE and GRADIENT trials showed meaningful, durable improvements in the signs and symptoms of Cushing's syndrome without many serious adverse events associated with currently approved medications, including hypokalemia, endometrial hypertrophy, vaginal bleeding, adrenal insufficiency or QT prolongation.
  • Progress Across Oncology Development ProgramsBELLA Arm B, evaluating relacorilant in platinum-sensitive ovarian cancer, was nearing completion of enrollment, while BELLA Arm C, evaluating endometrial cancer, had completed enrollment. The TRIDENT trial is evaluating relacorilant as a potential first-line treatment for pancreatic cancer, SYNERGY is evaluating nenocorilant with nivolumab across a broad range of solid tumors, and a University of Chicago-led Phase II trial is evaluating relacorilant with enzalutamide in early-stage prostate cancer. Results from these studies are expected by the end of next year.
  • MASH Trial Showed Liver Activity and TolerabilityIn the Phase IIb MONARCH study, patients receiving 200 milligrams of miricorilant twice weekly experienced a significantly larger reduction in liver fat than patients receiving 100 milligrams twice weekly. Patients receiving 100 milligrams twice weekly experienced an absolute fibrosis improvement of 19.2% in 48 weeks. Miricorilant was very well tolerated, with adverse-event rates virtually indistinguishable between the miricorilant and placebo arms.
  • Planned Higher-Dose MASH StudyThe company plans to begin a Phase II study evaluating 100 milligrams of miricorilant daily, using three weeks on treatment followed by one week off over 24 weeks. The study is intended to evaluate whether higher dosing can produce additional reductions in liver fat and improvements in fibrosis while minimizing ALT rises and preserving tolerability.
  • ALS Program Advancing Toward Phase IIIIn the Phase II DAZALS trial, treatment with a cortisol modulator resulted in a profound reduction in early mortality. The company plans to begin a Phase III study in ALS next year.
  • Broad GR Antagonism Platform StrategyManagement believes selective glucocorticoid receptor antagonists may benefit solid-tumor patients by bolstering the immune system's ability to combat cancer, sensitizing tumors to chemotherapy and blocking growth pathways for cancer cells. The company plans to evaluate Lifyorli and relacorilant in combinations with chemotherapy, antibody-drug conjugates and immunotherapy.

CORT Earnings History

CORT earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 02, 20272026 (Q4)1.12-0.2――
Nov 03, 20262026 (Q3)0.841.010.16531.25% (+0.85)
Jul 29, 20262026 (Q2)0.020.360.2924.14% (+0.07)
Apr 30, 20262026 (Q1)-0.11-0.300.17-276.47% (-0.47)
Feb 24, 20262025 (Q4)0.330.200.26-23.08% (-0.06)
Nov 04, 20252025 (Q3)0.160.160.41-60.98% (-0.25)
Jul 31, 20252025 (Q2)0.190.290.32-9.38% (-0.03)
May 05, 20252025 (Q1)0.140.170.25-32.00% (-0.08)
Feb 26, 20252024 (Q4)0.430.260.28-7.14% (-0.02)
Oct 30, 20242024 (Q3)0.280.410.2846.43% (+0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed